Amgen Inc. $AMGN Stock Purchased by Private Wealth Asset Management LLC

Private Wealth Asset Management LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 151.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,592 shares of the medical research company’s stock after buying an additional 1,561 shares during the quarter. Private Wealth Asset Management LLC’s holdings in Amgen were worth $1,193,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its position in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp boosted its position in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after buying an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after buying an additional 605,928 shares during the period. Bank of America Corp DE acquired a new stake in shares of Amgen in the second quarter valued at about $1,831,903,000. Finally, Amundi grew its stake in shares of Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after buying an additional 512,883 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. Argus boosted their price target on Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research report on Thursday, November 12th. Leerink Partners increased their price objective on shares of Amgen from $395.00 to $464.00 and gave the company a “market perform” rating in a research report on Thursday, November 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $410.00 price objective on shares of Amgen in a research report on Wednesday, September 23rd. Scotiabank lifted their price objective on shares of Amgen from $500.00 to $530.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 4th. Finally, Truist Financial boosted their target price on shares of Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $428.62.

Get Our Latest Report on Amgen

Amgen Trading Down 0.8%

Shares of AMGN opened at $435.52 on Friday. The company has a market capitalization of $235.58 billion, a P/E ratio of 25.26, a P/E/G ratio of 3.22 and a beta of 0.43. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The stock has a 50-day moving average price of $430.44 and a 200 day moving average price of $383.81.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the previous year, the business earned $5.64 EPS. Amgen’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 23.41 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is currently 58.47%.

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Articles

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.